But I think another piece of news is more exciting: new clinical trials the company plans to conduct of Provenge and a follow-up therapy for bladder cancer.
In reality, the scans are more likely to pick up "incidentalomas"--blips that don't necessarily mean anything but require a follow-up test, says Dr. Roseanne Leipzig, professor of clinical and geriatric medicine at Mount Sinai School of Medicine.